Stock-Based Compensation, Restricted Stock and Stock Options (Tables)

9 Months Ended

Dec. 31, 2019

Share-based Payment Arrangement [Abstract]

Schedule of stock based compensation expenses

	Three months ended December 31,				Nine months ended December 31,
	2019		2018		2019		2018
Research and development expenses	$	455,820	$	113,740	$	1,437,334	$	346,586
Selling, general and administrative expenses		896,291		92,631		2,781,142		296,917
Total stock-based compensation	$	1,352,111	$	206,371	$	4,218,476	$	643,503

Schedule of restricted stock awards

	Number of Shares			Weighted Average Grant-Date Fair Value
Unvested at March 31, 2019		-		$	-
Granted		6,000,000		$	0.82
Vested		(1,499,994	)	$	0.82
Unvested at December 31, 2019 (Unaudited)		4,500,006		$	0.82

Schedule of stock options

	Shares Underlying Options		Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (Years)		Aggregate Intrinsic Value
Outstanding at March 31, 2019		5,813,500	$	0.18		9.2	$	3,720,395
Outstanding at December 31, 2019 (Unaudited)		5,813,500	$	0.18		8.5	$	3,313,450
Exercisable at December 31, 2019 (Unaudited)		3,008,436	$	0.19		8.5	$	1,672,452